Zacks Small Cap Research – MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial … Read more

Zacks Small Cap Research – OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR – Go Health Pro

NASDAQ:AEMD Anthony Krause: Hello and welcome to Virtual Investor Conferences. My name is Anthony Krause, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we’re very pleased you have joined us for our next live presentation from Aethlon Medical. Their session will be moderated by Marla Marin, senior Analyst at Zacks … Read more

Final destination or important interim step? – Go Health Pro

Final destination or important interim step? – Go Health Pro

Markus Frischhut, Jean Monnet Professor (EU law, ethics and values) at Management Center Innsbruck, Austria and Adjunct professor at ‘Alma Mater Studiorum – Università di Bologna’, Italy Art credit: William Hogarth, An Election: the Polling   As ECJ President Koen Lenaerts aptly confirmed in a paper on “mutual (yet not blind) trust”, “[i]t is said … Read more

x